FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
wasinington,	D.C.	20049

STATEMENT	OF	CHANGES	IN BE	NEFICIAL	OWNERS	HIP

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* O'NEIL PATRICK R. (Last) (First) (Middle) C/O IONIS PHARMACEUTICALS, INC.						Issuer Name and Ticker or Trading Symbol IONIS PHARMACEUTICALS INC [IONS] Jate of Earliest Transaction (Month/Day/Year) 01/15/2021] (Che	Relationship of Reporting Person(s) to Issuer (Check all applicable) Director				
(Street) CARLSI (City)			92010 (Zip)		4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Deriv 1. Title of Security (Instr. 3) 2. Transa Date (Month/D			sactio	ction 2A. Deemed Execution Date,		3. 4. Securities Ac Transaction Code (Instr. 8)		s Acquired	(A) or	5. Amount of Securities Beneficially Owned Following		6. Ownersh Form: Dire (D) or Indir ng (I) (Instr. 4)		'. Nature of ndirect Beneficial Ownership				
								Code	v	Amount	(A) or (D)	Price	Reported Transacti (Instr. 3 a	on(s)			Instr. 4)	
Common Stock 01/15/				15/202	2021 01/15/2021		2021	M ⁽¹⁾		16,504 ⁽¹⁾		\$ <mark>0</mark>	37,	37,682		D		
Common Stock 01/15/			15/202	/2021 01/15/2021		2021	F ⁽²⁾		5,856(2)	D	\$61.28	31,826			D			
			Table II -								osed of, c			Owned				
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, or Exercise (Month/Day/Year) if any		ate,		ransaction ode (Instr.) Ac Dis (D)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Exerc tion Da //Day/\			ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti	e s illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	on(a)		
Restricted Stock Units	(3)(4)	01/15/2021	01/15/202	21	A		25,868		(5))	(5)	Common Stock	25,868	\$0	25,86	8	D	
Restricted Stock Units	(4)	01/15/2021	01/15/202	21	M			16,504	(5))	(5)	Common Stock	16,504	\$0	32,25	3	D	

Explanation of Responses:

- 1. Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.
- 2. Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
- 3. Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
- 4. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
- 5. Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

Remarks:

/s/Patrick R. O'Neil

01/20/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.